Saturday, July 18, 2026

HomeHealth NewsFDA approves first rapid-acting insulin biosimilar for patients with diabetes

FDA approves first rapid-acting insulin biosimilar for patients with diabetes

- Advertisement -

The U.S. Food and Drug Administration has approved Sanofi-Aventis’s Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

Click here to view the original article.

- Advertisment -
- Advertisement -

Recently Viewed